Cancer Research UK logo.
SearchDonate
  • Search

A trial to find the best way to give radiotherapy for people with small cell lung cancer (CONVERT)

Overview

Cancer types:

Lung cancer, Small cell lung cancer

Status:

Results

Phase:

Phase 3

Details

This trial looked at whether it is best to have radiotherapy twice or once a day. It was for people whose small cell lung cancer hadn’t spread elsewhere in the body and who were having cisplatin and etoposide chemotherapy.

Cancer Research UK supported this trial.

Recruitment start: 7 April 2008

Recruitment end: 31 July 2013

How to join

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Professor Corinne Faivre-Finn

Supported by

Cancer Research UK

The Christie NHS Foundation Trust

The Manchester Academic Health Science Centre Clinical Trials Unit

Experimental Cancer Medicine Centre (ECMC)

European Organisation for Research and Treatment of Cancer (EORTC)

NIHR Clinical Research Network: Cancer

National Institute of Canada Clinical Trials Group (NCIC CTG)

Spanish Lung Cancer Group (GECP)

French Lung Cancer Group (GFPC)

Other information

This is Cancer Research UK trial number CRUK/07/005.

We have more information about the work of Professor Corinne Faivre-Finn.

Last reviewed: 7 September 2016

CRUK internal database number: 893

The Dangoor Education logo.

Dangoor Education

About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education

Patient Information Forum. Trusted Information Creator.
Plain English Campaign award.

Help and support

An icon of a hand shake.

Questions for your doctor

What to ask your doctor about clinical trials.

An icon of two speech bubbles, indicating a conversation.

Cancer chat forum

Meet and chat to other cancer people affected by cancer.

An icon of a landline phone.

Nurse helpline

Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.